Colites microscopiques--quoi de neuf ? [Microscopic colitis: update 2014].

Microscopic colitis, which includes lymphocytic colitis and collagenous colitis, represents a frequent cause of chronic watery diarrhea especially in the elderly population. Several medications, such as nonsteroidal antiinflammatory drugs, proton pump inhibitors or antidepressants, as well as cigarette smoking have been recognized as risk factors for microscopic colitis. The diagnosis of microscopic colitis is based on a macroscopically normal ileo-colonoscopy and several biopsies from the entire colon, which demonstrate the pathognomonic histopathologic findings. Therapy is mainly based on the use of budesonide. Other medications, such as mesalazine, cholestyramine and bismuth, have been evaluated as well but the evidence is less solid.

Involvement of 4E-BP1 in the protection induced by HDLs on pancreatic beta cells.

High-density lipoproteins (HDLs) protect pancreatic beta cells against apoptosis. This property might relate to the increased risk to develop diabetes in patients with low HDL blood levels. The mechanisms by which HDLs protect beta cells are poorly characterized however. Here we used a transcriptomic approach to identify genes differentially modulated by HDLs in beta cells subjected to apoptotic stimuli. The transcript encoding 4E-BP1 was up-regulated by serum starvation and HDLs blocked this increase. 4E-BP1 inhibits cap-dependent translation in its non- or hypo-phosphorylated state but it looses this ability when hyper-phosphorylated. At the protein level, 4E-BP1 was also up-regulated in response to starvation and IL1beta and this was blunted by HDLs. While an ectopic increase of 4E-BP1 expression induced beta cell death, silencing 4E-BP1 increase with shRNAs inhibited the apoptotic-inducing capacities of starvation. HDLs can therefore protect beta cells by blocking 4E-BP1 protein expression but this is not the sole protective mechanism activated by HDLs. Indeed, HDLs blocked apoptosis induced by ER stress with no associated decrease in total 4E-BP1 induction. Although, HDLs favored the phosphorylation, and hence the inactivation of 4E-BP1 in these conditions, this appeared not to be required for HDL protection. Our results indicate that HDLs can protect beta cells through modulation of 4E-BP1 depending on the type of stress stimuli.

Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.

Cytomegalovirus (CMV) is generally considered the most significant pathogen to infect patients following organ transplantation. Significant improvements have been achieved in the management of CMV disease over recent years, especially since the introduction of oral drugs such as oral ganciclovir followed by valganciclovir (VGC), a prodrug of ganciclovir with enhanced bioavailability. Several randomized controlled trials have shown that VGC is an efficacious and convenient oral drug to prevent or treat CMV disease in solid-organ transplant recipients. In this article, we discuss the clinical and pharmacological experience with the use of VGC for the management of CMV in solid-organ transplant recipients. Finally, novel strategies to further reduce the incidence of CMV disease after transplantation are also reviewed.

The Power of Images in Antonio Agustin's. Diálogos de Medallas, inscripciones y otras antigüedades (1587)

Socias ofereix una àmplia mirada sobre l'ús de les imatges en les obres de numismàtica primerenques. Diàlegs de medalles, d'Antonio Agustín

Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme.

AIM: To perform a systematic review on the costs and cost-effectiveness of concomitant and adjuvant temozolomide with radiotherapy for the treatment of newly diagnosed glioblastoma compared with initial radiotherapy alone. METHODS: Electronic databases were searched for relevant publications on costs and cost-effectiveness until October 2008. RESULTS: We found four relevant clinical trials, one cost study and two economic models. The mean survival benefit in the radiotherapy plus temozolomide group varied between 0.21 and 0.25 life-years. Treatment costs were between 27,365 euros and 39,092 euros. The costs of temozolomide amounted to approximately 40% of the total treatment costs. The incremental cost-effectiveness ratios found in the literature were 37,361 euros per life-year gained and 42,912 euros per quality-adjusted life-year gained. However, the models are not comparable because different outcomes are used (i.e., life-years and quality-adjusted life-years). CONCLUSION: Although the models are not comparable according to outcome, the incremental cost-effectiveness ratios found are within acceptable ranges. We concluded that despite the high temozolomide acquisition costs, the costs per life-year gained and the costs per quality-adjusted life-year gained are comparable with other accepted first-line treatments with chemotherapy in patients with cancer.

Pièces relatives à l'histoire de la ville de TULLE. I

Contient : Copies de bulles, lettres royaux, etc., concernant l'histoire de la ville de Tulle (1372-1547), extraites des archives et de la Bibliothèque du Roi, des archives de l'église de Tulle et d'originaux en la possession de Baluze ; Accord entre l'évêque et le chapitre de Tulle (1429), extrait du « Codex magnorum statutorum » ; Accords entre Louis d'Aubusson, évêque de Tulle, et Guichard de Comborn, abbé d'Uzerche (1456-1465) ; Hommage fait par Charles de Malemont à Clément de Brillac, évêque de Tulle (18 avril 1503) ; « Acta primi ingressus Hugonis de Albuconia, episcopi Tutellensis » (1451) ; « Acta primi ingressus Dionysii de Barro, episcopi Tutelensis » (1472) ; Serments prêtés par les évêques de Tulle de respecter les libertés de la ville (1495-1561) ; Description de l'église cathédrale de Tulle ; Copie figurée d'une inscription de l'église de Moissac, relative à la dédicace de cette église en 1063 (Cf. Gall. christ., t. I, col. 158) ; Pièces relatives à l'envoi du comte de Ventadour comme gouverneur du Limousin (1634) ; originaux ; Catalogus abbatum et episcoporum Tullensium, par Et. Baluze (placard imprimé ; Tulle, 1669) ; Procès-verbaux « touchant l'argent que la ville a prins des coffres du Roi » (31 octobre 1685) ; copies contemporaines ; Lettres royaux portant convocation de l'assemblée des trois ordres à Tulle pour l'envoi de députés aux Etats généraux (août 1614) ; placard imprimé ; Confirmation par Louis XIII du droit, pour les habitants de Tulle, de percevoir un octroi aux portes de la ville (16 mars 1611-22 novembre 1612) ; Défense faite aux curés de Saint-Pierre et de Saint-Jacques de Tulle de marier des étrangers sans autorisation du maire et des consuls (10 mars 1586) ; Extrait des registres de la Maison de ville de Tulle (1587-1588) ; « Estat de la recette que j'ay fait durant mon quartier, qui a commencé le 1er de septembre 1599 et finy le dernier de novembre audit an ; » original, sans indication de provenance ; Etat de sommes à percevoir dans les diverses parroisses de l'évêché de Tulle (1589) ; original ; Inventaire de titres concernant les vicomtes de Comborn (1441-1489) ; Accensement des revenus de la prévôté de Clergoux (21 janvier 1531-1532 n. st.) ; copie contemporaine ; Pièces relatives au différend entre le vicaire général et le chapitre de Tulle au sujet de l'ouverture du jubilé (avril 1656) ; Lettre du vicaire général, Guillaume Dumas, à M. Javel, sénéchal de Turenne (21 juillet 1655) ; Bulletins de service pour la garde des portes de la ville de Tulle (1586) ; originaux ; Lettre écrite de Tulle [à Baluze ?] par M. Collier (13 mars 1679) ; Mémoires sur la ville de Tulle, par M. Brivazat, vissenéchal de Tulle ; Procès-verbal d'une assemblée de conseillers de ladite ville (20 mars 1586) ; Lettre de G. de Juré aux consuls de la ville de Tulle (s. d.) ; original ; Requête présentée à « nossieurs des Comptes » par Bertrand Fagerdie (s. d.) ; original ; Mémoire sur la gestion du même au siège royal de Tulle (1551) ; Accord entre les habitants de Tulle et ceux de Brive pour le rétablissement du siège royal (1553) ; copie contemporaine ; Lettre d'Etienne de l'Estang à [Antoine] de Noailles, lieutenant du roi en Guyenne, relative à la même affaire (1551) ; copie donnée à Baluze par vyon d'Herouval en 1684 ; Accord entre B. Fagerdie et Antoine de La Tour, chanoine de Tulle (1561) ; original ; Enquête faite au sujet de l'anoblissement de Guillaume de Marne, lieutenant-général au siège de Tulle (1597) ; original ; Anoblissement de Pierre Geneste et de divers autres jurats de la ville de Bordeaux (juin 1589) ; Rôle de taille et taillon de la ville de Tulle (février 1595) ; original ; Factum pour le syndic du clergé du diocèse de Tulle contre les prétendus reformez d'Argentat ; imprimé de 4 p. in-4°, s. d., avec une note relative à la destruction du temple d'Argentat en 1682 ; Mandements et ordonnances des évêques et des vicaires généraux de Tulle (1668-1696) ; placards imprimés

Allergic bronchopulmonary aspergillosis: the hunt for a diagnostic serological marker in cystic fibrosis patients.

The diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis patients remains challenging, mainly owing to overlapping symptoms of the underlying lung disease with clinical symptoms of ABPA. In addition, a varying mixture of diagnostic criteria, including clinical status, radiological findings and immunological measurements, has led to confusion and differing recommendations. In order to help simplify as well as standardize the diagnostic criteria for ABPA, different serological markers have been evaluated in the last 20 years and their usefulness has been assessed in many clinical studies. This review presents current diagnostic criteria of ABPA, with a special focus on serum markers supporting the diagnosis and explains why the hunt for a serological marker for ABPA is still ongoing.

Cutaneous leishmaniasis: progress towards a vaccine.

Leishmaniases are vector-borne diseases due to the protozoan parasite Leishmania . Since no prevention method is available and as current therapy is costly, often poorly tolerated and not always efficacious, the development of alternative therapies, including vaccines, constitutes the priority in the fight of Leishmania infection. This review focuses on recent advances in the development of vaccines against leishmaniasis, with emphasis on the cutaneous form. Indeed, the fact that recovery from leishmaniasis is associated with immunity against new infection provides a rational basis for the development of vaccination strategy against infection with Leishmania . Evidence from animal studies demonstrate that protection can be achieved following infection with live-attenuated Leishmania as well as through immunization with purified proteins or DNA vaccines. In addition, recent results have shown that immunization against the saliva of the insect vector could have synergistic effects with conventional vaccination. Finally, vaccination using dendritic cells was recently demonstrated as a possible tool for Leishmania vaccination.

Pathogenesis of arenavirus hemorrhagic fevers.

Viral hemorrhagic fevers (VHFs) caused by arenaviruses belong to the most devastating emerging human diseases and represent serious public health problems. Arenavirus VHFs in humans are acute diseases characterized by fever and, in severe cases, different degrees of hemorrhages associated with a shock syndrome in the terminal stage. Over the past years, much has been learned about the pathogenesis of arenaviruses at the cellular level, in particular their ability to subvert the host cell's innate antiviral defenses. Clinical studies and novel animal models have provided important new information about the interaction of hemorrhagic arenaviruses with the host's adaptive immune system, in particular virus-induced immunosuppression, and have provided the first hints towards an understanding of the terminal hemorrhagic shock syndrome. The scope of this article is to review our current knowledge on arenavirus VHF pathogenesis with an emphasis on recent developments.

Potential and limitations of regulatory T-cell therapy in solid organ transplantation.

Over the past few years, the therapeutic potential of Treg has been highlighted in the field of autoimmune diseases and after allogeneic transplantation. The first hurdle for the therapeutic use of Treg is their insufficient numbers in non-manipulated individuals, in particular when facing strong immune activation and expanding effector cells, such as in response to an allograft. Here we review current approaches being explored for Treg expansion in the perspective of clinical therapeutic protocols. We describe different Treg subsets that could be suitable for clinical application, as well as discuss factors such as the required dose of Treg, their antigen-specificity and in vivo stability, that have to be considered for optimal Treg-based immunotherapy in transplantation. Since Treg may not be sufficient as stand-alone therapy for solid organ transplantation in humans, we draw attention to possible hurdles and combination therapy with immunomodulatory drugs that could possibly improve the in vivo efficacy of Treg.